Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia (Q34060237)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

Omar Abdel-Wahab

1 reference

ORCID Public Data File 2021

author name string

D A Pollyea

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

H E Kohrt

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

L Gallegos

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

M E Figueroa

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

O Abdel-Wahab

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

B Zhang

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

S Bhattacharya

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

J Zehnder

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

M Liedtke

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

J R Gotlib

10

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

S Coutre

11

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

C Berube

12

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

A Melnick

13

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

R Levine

14

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

B S Mitchell

15

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

B C Medeiros

16

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

publication date

28 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

893-901

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Acute myeloid leukemia in the elderly

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Age and acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Who is fit for allogeneic transplantation?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

DNA methylation and gene silencing in cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Epigenetic regulation of normal and malignant hematopoiesis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Aging, DNA methylation and cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Treatment of acute myelogenous leukemia with outpatient azacitidine

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Mechanism of action of lenalidomide in hematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Dose escalation of lenalidomide in relapsed or refractory acute leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Design and analysis of phase I clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

A comparison of two methods for screening CEBPA mutations in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Comparative isoschizomer profiling of cytosine methylation: the HELP assay

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Immunomodulation in myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

21 January 2018

Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.294

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2011.294

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34060237&oldid=2196186757"